DeepScribe vs Freed
This pairing nearly sorts itself, because each vendor states plainly what it is not for. DeepScribe is explicit that its fit is complex longitudinal specialty care rather than short low acuity visits: oncology as its center of gravity, tuned models for six further specialties, bidirectional integration writing discrete EHR fields, and the highest independent rating in the lane at 98.8 on the KLAS Emerging Company Spotlight, sold through enterprise sales with no trial. Freed states its strength is primary care and that specialty depth beyond it is a known weakness: published pricing from $39 a month, a Business Associate Agreement by default, same day setup, and a browser extension push with no native write back. If your failure mode is specialty documentation, oncology above all, and you can run a procurement process, start with DeepScribe. If your failure mode is a primary care caseload and needing working notes this week, start with Freed. Match the tool to the caseload; neither pretends to cover the other's.
- Specialty depth is the requirement: oncology as its center of gravity with a reported 40 percent of US cancer care visits, tuned models for six further specialties, and an explicit fit for complex longitudinal specialty care, exactly the caseload Freed states is its weakness.
- The evidence is one sided: a 98.8 KLAS Emerging Company Spotlight score with A plus marks across all six categories and an August 2025 Journal of Clinical Pathways study in oncology, where Freed's clinical evidence is unassessed on this index.
- Structured data must land in the chart: bidirectional integration writes discrete EHR fields with HCC, CPT, and ICD-10 suggestions built into the note, in more than 110 languages, against Freed's browser extension push with no native write back.
- You can see the whole cost before talking to anyone: $39 Starter, $79 Core unlimited, $119 Premier with EHR Push and coding, and a seven day trial with no credit card, where DeepScribe runs enterprise sales with no self serve signup and no trial.
- Compliance comes standard at the entry tier: a HIPAA Business Associate Agreement by default on all tiers, SOC 2 Type II, automatic deletion of recordings, and an opt out from model training.
- Zero deployment is the feature: sign up and generate notes the same day; community health center Camarena Health deployed 55 clinicians across 24 sites without formal implementation, on a base of more than 25,000 clinicians and 32 million transcribed visits.
Side-by-Side
| Axis | D DeepScribe |
F Freed |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | — | — |
| Model and Technology Transparency | — | — |
| Clinical and Operational Evidence | — | |
| AI Safety and PHI Stewardship | — | |
| HIPAA and BAA Posture | — | |
| Security Certifications and Trust Center | — | — |
| FDA and Regulatory Status | — | — |
| AI Governance and Bias Disclosure | — | — |
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | — | — |
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Visit volumes and market share figures for both vendors are vendor published, including DeepScribe's oncology share and Freed's 32 million transcribed visits. Both vendors are unusually candid about their own scope, and this comparison leans on that candour: DeepScribe states its fit is complex longitudinal specialty care rather than short low acuity visits, and Freed's specialty depth outside primary care is a stated weakness with procedure heavy documentation needing more editing. DeepScribe's KLAS scores are buyer survey based, with the Emerging Company Spotlight a different KLAS instrument from the Best in KLAS category awards held elsewhere in this lane; Freed's clinical evidence is unassessed on this index. Freed's pricing is fully published; DeepScribe publishes none, with third party estimates of $350 to $500 per provider per month and some reports near $750 recorded as unconfirmed estimates.